Portfolio Co Investors 2026 for Lilly Asia Ventures: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.
Lilly Asia Ventures accounts for 54 tracked companies with verified cap-table data, 54 of which disclose round sizes totalling $9.6B. The median disclosed raise is $155M, and the largest is Abogen Biosciences at $700M, ahead of Alumis ($529M) and Gracell Biotechnologies ($520M).
The names that recur most often on these co-invested cap tables are Lilly Asia Ventures (54 companies), OrbiMed (12 companies), Qiming Venture Partners (9 companies), Vivo Capital (7 companies), Sherpa Healthcare Partners (7 companies), Cormorant Asset Management (5 companies). By latest disclosed round, the market skews Series B (16), Series A (13), Series C (11), IPO (4).
Companies tracked: 54
Disclosed funding total: $9.6B across 54 companies
Median disclosed raise: $155M
Largest raise: Abogen Biosciences — $700M
Stage mix: Series B 16 · Series A 13 · Series C 11 · IPO 4
